Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients …

Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted ...

Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data highlighting the potential of ...

Daily Mail's health editor reveals the best tech, supplements and gear... from bidets to weighted vests and creatine

Whether it is a new probiotic to help with my digestion, a pillow to ease neck pain or a water bottle to filter out ...

They are the wellness fads of the year. Now the Daily Mail tests them to reveal which ones REALLY live up to the hype

Whether it is a new probiotic to help with my digestion, a pillow to ease neck pain or a water bottle to filter out ...

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...